New pill aims to keep leukemia in check for patients left behind by transplant barriers
NCT ID NCT06370000
First seen Mar 11, 2026 · Last updated May 23, 2026 · Updated 11 times
Summary
This study tests whether an oral medication (azacitidine) can help prevent acute myeloid leukemia from coming back in patients who are eligible for a stem cell transplant but cannot get one due to racial or socioeconomic reasons. About 12 adults whose leukemia is in remission will take the medication for several months. The goal is to see if this approach is practical and helps keep the cancer away.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Virginia Commonwealth University
RECRUITINGRichmond, Virginia, 23298, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.